AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25899895 — intervention group
Group type: EXPERIMENTAL
Intervention: NIL-CHF intervention (nurse-led, multidisciplinary programme of home/clinic visits)
Number of subjects: 624
Study 25899895 — intervention group
Group type: EXPERIMENTAL
Intervention: NIL-CHF intervention
Number of subjects: 624
Study 25899895 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 624
Study 23221187 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% povidone iodine aqueous solution (PI)
Number of subjects: 12904
Study 23221187 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% iodine tincture (IT)
Number of subjects: 12904
Study 23221187 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate in 70% isopropyl alcohol (CHG)
Number of subjects: 12904
Study 20527505 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum containing sodium tripolyphosphate (1%)
Number of subjects: 111
Study 20527505 — intervention group
Group type: COMPARATOR
Intervention: Placebo sugar‐free chewing gum
Number of subjects: 111
Study 18528292 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-occluded retrograde transvenous obliteration (BRTO)
Number of subjects: 237
Study 18528292 — intervention group
Group type: COMPARATOR
Intervention: Control group (no BRTO)
Number of subjects: 237
Study 16638499 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (2 mg/kg/day for 4 weeks)
Number of subjects: 22
Study 16638499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 16638499 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 22
Study 12789036 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure relief to 0 mm Hg
Number of subjects: 12
Study 12789036 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure relief to 5 mm Hg
Number of subjects: 12
Study 12789036 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure relief to 10 mm Hg
Number of subjects: 12
Study 10949538 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) melatonin, average final dose 5.7 mg (2-12 mg)
Number of subjects: 42
Study 10949538 — intervention group
Group type: COMPARATOR
Intervention: Fast-release (FR) melatonin
Number of subjects: 42
Study 9012300 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure support ventilation (PSV) with varying inspiratory flow rates (pressurization times of < 0.1, 0.5, 1, 1.5, 2 seconds).
Number of subjects: 12
Study 9012300 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure support ventilation (PSV) with decreasing inspiratory flow rates.
Number of subjects: 12
Study 9012300 — intervention group
Group type: COMPARATOR
Intervention: Control group (no or minor nonobstructive lung pathology).
Number of subjects: 12
Study 8412050 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (PRAZ)
Number of subjects: 6
Study 8412050 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CTL)
Number of subjects: 6
Study 2864857 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine monotherapy (10 mg three times daily)
Number of subjects: 12
Study 2864857 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol monotherapy (100 mg twice daily)
Number of subjects: 12
Study 2864857 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (100 mg metoprolol twice daily plus 10 mg nifedipine three times daily)
Number of subjects: 12
Study 2864857 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 12
Study 30753892 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 110
Study 30753892 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 110
Study 30753892 — intervention group
Group type: COMPARATOR
Intervention: Meta-analysis of PEAR-2 and PEAR
Number of subjects: 110
Study 26778468 — intervention group
Group type: EXPERIMENTAL
Intervention: Same label
Number of subjects: 80
Study 26778468 — intervention group
Group type: EXPERIMENTAL
Intervention: Different labels
Number of subjects: 80
Study 26778468 — intervention group
Group type: COMPARATOR
Intervention: Nonlinguistic sounds
Number of subjects: 80
Study 25284993 — intervention group
Group type: EXPERIMENTAL
Intervention: LSS-tele
Number of subjects: 27
Study 25284993 — intervention group
Group type: EXPERIMENTAL
Intervention: LSS-direct
Number of subjects: 27
Study 25284993 — intervention group
Group type: COMPARATOR
Intervention: UCS
Number of subjects: 27
Study 21752586 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-bearing TKA
Number of subjects: 119
Study 21752586 — intervention group
Group type: COMPARATOR
Intervention: Fixed-bearing TKA
Number of subjects: 119
Study 20809058 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS (1000 pulses of subthreshold 10 Hz rTMS for 10 days)
Number of subjects: 28
Study 20809058 — intervention group
Group type: COMPARATOR
Intervention: Control rTMS (sham treatment)
Number of subjects: 28
Study 19034097 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity training model (computerized virtual reality bronchoscopy simulator)
Number of subjects: 28
Study 19034097 — intervention group
Group type: COMPARATOR
Intervention: Low-fidelity training model (nonanatomic model guided by experts)
Number of subjects: 28
Study 19034097 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (low-fidelity and high-fidelity)
Number of subjects: 28
Study 15929814 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients undergoing selective PCI
Number of subjects: 1294
Study 15929814 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic patients undergoing selective PCI
Number of subjects: 1294
Study 12663288 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified beverage with 10 micronutrients at physiologic doses
Number of subjects: 0
Study 12663288 — intervention group
Group type: COMPARATOR
Intervention: Nonfortified beverage (control)
Number of subjects: 0
Study 12663288 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified beverage
Number of subjects: 0
Study 10378552 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 60 mg daily for 14 days
Number of subjects: 14
Study 10378552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 10378552 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 14
Study 10378552 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after washout)
Number of subjects: 14
Study 8650875 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of normal saline (15 mL/kg)
Number of subjects: 28
Study 8650875 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (1 mg/kg; maximum, 40 mg)
Number of subjects: 28
Study 8650875 — intervention group
Group type: COMPARATOR
Intervention: Fasting state
Number of subjects: 28
Study 1632390 — intervention group
Group type: EXPERIMENTAL
Intervention: IS-5-MN (20 mg) at 8 a.m.
Number of subjects: 18
Study 1632390 — intervention group
Group type: EXPERIMENTAL
Intervention: IS-5-MN (20 mg) at 2 p.m.
Number of subjects: 18
Study 1632390 — intervention group
Group type: COMPARATOR
Intervention: Placebo at 8 a.m.
Number of subjects: 18
Study 1632390 — intervention group
Group type: COMPARATOR
Intervention: Placebo at 2 p.m.
Number of subjects: 18
Study 4056843 — intervention group
Group type: COMPARATOR
Intervention: Recombinant DNA-derived interferon alpha (rIFN alpha A) at a low dose of 2 X 10(6) U/m2 intramuscularly daily
Number of subjects: 56
Study 4056843 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant DNA-derived interferon alpha (rIFN alpha A) at a high dose of 20 X 10(6) U/m2 intramuscularly daily
Number of subjects: 56
Study 4056843 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant DNA-derived interferon alpha (rIFN alpha A) at a high dose (20 X 10(6) U/m2)
Number of subjects: 56
Study 4056843 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant DNA-derived interferon alpha (rIFN alpha A)
Number of subjects: 56
Study 31170224 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-chosen music (10 minutes)
Number of subjects: 80
Study 31170224 — intervention group
Group type: COMPARATOR
Intervention: Active control (10 minutes of listening to an experimenter-chosen radio documentary)
Number of subjects: 80
Study 31170224 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group (younger vs older adults)
Number of subjects: 80
Study 28795387 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg/day orally) plus Fuzheng Kang'ai Formula (250 mL, twice per day, orally)
Number of subjects: 70
Study 28795387 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib (250 mg/day orally)
Number of subjects: 70
Study 26891861 — intervention group
Group type: EXPERIMENTAL
Intervention: 8h monitoring interval
Number of subjects: 1346
Study 26891861 — intervention group
Group type: COMPARATOR
Intervention: 12h monitoring interval
Number of subjects: 1346
Study 24686841 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-density nonwords
Number of subjects: 61
Study 24686841 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density nonwords
Number of subjects: 61
Study 20123223 — intervention group
Group type: EXPERIMENTAL
Intervention: Turn-mob program (passive turning and mobilization by a trained relative)
Number of subjects: 223
Study 20123223 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (turning by nursing staff)
Number of subjects: 223
Study 16361173 — intervention group
Group type: EXPERIMENTAL
Intervention: Penehyclidine hydrochloride (PH) 0.02 mg/kg combined with neostigmine 0.03 mg/kg
Number of subjects: 80
Study 16361173 — intervention group
Group type: COMPARATOR
Intervention: Atropine 0.02 mg/kg combined with neostigmine 0.03 mg/kg
Number of subjects: 80
Study 12143227 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg terlipressin i.v. every 4 hours for 2 days (group I)
Number of subjects: 86
Study 12143227 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg terlipressin i.v. every 4 hours for 5 days (group II)
Number of subjects: 86
Study 9491067 — intervention group
Group type: EXPERIMENTAL
Intervention: White dawn treatment (1.5 hours from 4:30 a.m. to 6:00 a.m. peaking at 250 lux)
Number of subjects: 12
Study 9491067 — intervention group
Group type: COMPARATOR
Intervention: Dim red dawn treatment (1.5 hours from 4:30 a.m. to 6:00 a.m. peaking at 2 lux)
Number of subjects: 12
Study 9491067 — intervention group
Group type: EXPERIMENTAL
Intervention: White dawn treatment
Number of subjects: 12
Study 7923305 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting nicardipine
Number of subjects: 35
Study 7923305 — intervention group
Group type: COMPARATOR
Intervention: Standard nicardipine tablets
Number of subjects: 35
Study 7923305 — intervention group
Group type: COMPARATOR
Intervention: Long-acting nifedipine
Number of subjects: 35
Study 3044874 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone (500 mg)
Number of subjects: 53
Study 3044874 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol (500 mg)
Number of subjects: 53
Study 11811084 — intervention group
Group type: COMPARATOR
Intervention: Standard eradication treatment (lansaprasol 30 mg bid, clarithromycin 500 mg bid, amoxicillin 1 g bid for 14 days)
Number of subjects: 210
Study 11811084 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) 1000 mg/day plus standard treatment
Number of subjects: 210
Study 11811084 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) 1000 mg/day for 14 days
Number of subjects: 210
Study 11811084 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard regimen plus beta carotene (BC) 120 mg/day
Number of subjects: 210
Study 11811084 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta carotene (BC) 120 mg/day for 14 days
Number of subjects: 210
Study 11811084 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard regimen plus allicin 4200 micrograms/day
Number of subjects: 210
Study 11811084 — intervention group
Group type: EXPERIMENTAL
Intervention: Allicin 1200 micrograms/day for 14 days
Number of subjects: 210
Study 30589387 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week rehabilitation program consisting of ankle stretching and strengthening, balance training, and joint mobilizations, with daily home ankle-strengthening and stretching exercises.
Number of subjects: 20
Study 30589387 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week rehabilitation program
Number of subjects: 20
Study 29708388 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation treatment plus exercise intervention (ST + EX)
Number of subjects: 136
Study 29708388 — intervention group
Group type: COMPARATOR
Intervention: Smoking cessation treatment plus wellness education (ST + CTRL)
Number of subjects: 136
Study 26944609 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol administration
Number of subjects: 38
Study 26944609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 25312637 — intervention group
Group type: EXPERIMENTAL
Intervention: Type C lesions
Number of subjects: 3661
Study 25312637 — intervention group
Group type: COMPARATOR
Intervention: Bivalirudin monotherapy
Number of subjects: 3661
Study 25312637 — intervention group
Group type: COMPARATOR
Intervention: Heparin plus glycoprotein IIb/IIIa inhibitor
Number of subjects: 3661
Study 22931760 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 124
Study 22931760 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil
Number of subjects: 124
Study 22931760 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan plus Tadalafil
Number of subjects: 124
Study 22931760 — intervention group
Group type: COMPARATOR
Intervention: Watch for waiting
Number of subjects: 124
Study 20143642 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent ICS use
Number of subjects: 914
Study 20143642 — intervention group
Group type: COMPARATOR
Intervention: No ICS use
Number of subjects: 914
Study 20143642 — intervention group
Group type: EXPERIMENTAL
Intervention: Poorly controlled asthma
Number of subjects: 914
Study 17389305 — intervention group
Group type: EXPERIMENTAL
Intervention: LY451395 0.2 mg BID for 28 days and 1.0 mg BID thereafter (n = 90)
Number of subjects: 181
Study 17389305 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 91)
Number of subjects: 181
Study 14693973 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes case management
Number of subjects: 362
Study 14693973 — intervention group
Group type: COMPARATOR
Intervention: Traditional primary care treatment (Control)
Number of subjects: 362
Study 12154416 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion (n = 188)
Number of subjects: 381
Study 12154416 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline; n = 193)
Number of subjects: 381
Study 9840636 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated components fixed without cement
Number of subjects: 37
Study 9840636 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented components
Number of subjects: 37
Study 9840636 — intervention group
Group type: COMPARATOR
Intervention: Noncoated components fixed without cement
Number of subjects: 37
Study 8206467 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% podophyllotoxin
Number of subjects: 57
Study 8206467 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50% podophyllotoxin
Number of subjects: 57
Study 8206467 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution (70% ethanolic vehicle)
Number of subjects: 57
Study 8206467 — intervention group
Group type: EXPERIMENTAL
Intervention: Podophyllotoxin (both concentrations)
Number of subjects: 57
Study 2510257 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil, 600 micrograms
Number of subjects: 8
Study 2510257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 129853 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectinomycin hydrochloride (2.0 g)
Number of subjects: 0
Study 129853 — intervention group
Group type: COMPARATOR
Intervention: Aqueous penicillin combined with probenecid
Number of subjects: 0
Study 31676651 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial HPSF (structured physical activity sessions only)
Number of subjects: 1676
Study 31676651 — intervention group
Group type: EXPERIMENTAL
Intervention: Full HPSF (daily healthy lunch and structured physical activity sessions)
Number of subjects: 1676
Study 31676651 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 1676
Study 28448266 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal Continuous Oxygen Therapy (TCOT)
Number of subjects: 122
Study 28448266 — intervention group
Group type: COMPARATOR
Intervention: Moist Wound Therapy (MWT) with sham device (control)
Number of subjects: 122
Study 25491768 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day training, Lumio (magnifying glass with polarized light, 3Gen), Nikon digital camera, and 1 year of feedback on skin lesion pictures sent to the dermatologist.
Number of subjects: 78
Study 25491768 — intervention group
Group type: COMPARATOR
Intervention: 1-day training only (control group).
Number of subjects: 78
Study 24015629 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel
Number of subjects: 23
Study 24015629 — intervention group
Group type: COMPARATOR
Intervention: Traditional method
Number of subjects: 23
Study 21955757 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 20
Study 21955757 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined prone and upright position
Number of subjects: 20
Study 21955757 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 20
Study 19628408 — intervention group
Group type: COMPARATOR
Intervention: Green tea consumption (7 or more cups per day)
Number of subjects: 12251
Study 19628408 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea consumption
Number of subjects: 12251
Study 16863564 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium infantis 35624 at a dose of 1 x 10(8) cfu/mL
Number of subjects: 362
Study 16863564 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium infantis 35624 at a dose of 1 x 10(6) cfu/mL
Number of subjects: 362
Study 16863564 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium infantis 35624 at a dose of 1 x 10(10) cfu/mL
Number of subjects: 362
Study 16863564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 362
Study 15223089 — intervention group
Group type: EXPERIMENTAL
Intervention: Accu Drop (AD) plus counseling (C)
Number of subjects: 60
Study 15223089 — intervention group
Group type: COMPARATOR
Intervention: Placebo drop (PD) plus counseling (C)
Number of subjects: 60
Study 15223089 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (AD&C and PD&C)
Number of subjects: 60
Study 11262683 — intervention group
Group type: EXPERIMENTAL
Intervention: Triangular or half-sinusoidal stimuli of 400 ms duration
Number of subjects: 13
Study 11262683 — intervention group
Group type: EXPERIMENTAL
Intervention: Square wave stimuli
Number of subjects: 13
Study 11262683 — intervention group
Group type: COMPARATOR
Intervention: Control group (3 subjects)
Number of subjects: 13
Study 9048460 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable barrier (poly[lactic acid])
Number of subjects: 9
Study 9048460 — intervention group
Group type: COMPARATOR
Intervention: Expanded polytetrafluoroethylene (e‐PTFE) membranes
Number of subjects: 9
Study 7748346 — intervention group
Group type: EXPERIMENTAL
Intervention: Korsakoff alcoholics
Number of subjects: 0
Study 7748346 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Korsakoff alcoholics
Number of subjects: 0
Study 7748346 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study 3015019 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily acyclovir treatment (200 mg t.i.d.)
Number of subjects: 35
Study 3015019 — intervention group
Group type: COMPARATOR
Intervention: Weekend acyclovir treatment (400 mg t.i.d. on Saturday and Sunday)
Number of subjects: 35
Study 30286746 — intervention group
Group type: EXPERIMENTAL
Intervention: ART adherence support through peer influence and community engagement
Number of subjects: 7
Study 30286746 — intervention group
Group type: EXPERIMENTAL
Intervention: Addressing poverty and economic independence
Number of subjects: 7
Study 30286746 — intervention group
Group type: EXPERIMENTAL
Intervention: School attendance and privacy issues
Number of subjects: 7
Study 30286746 — intervention group
Group type: EXPERIMENTAL
Intervention: Family support and guardianship issues
Number of subjects: 7
Study 30286746 — intervention group
Group type: EXPERIMENTAL
Intervention: Managing multiple medications
Number of subjects: 7
Study 25830326 — intervention group
Group type: EXPERIMENTAL
Intervention: rVSV-ZEBOV vaccine (300,000 to 50 million PFU)
Number of subjects: 158
Study 25830326 — intervention group
Group type: EXPERIMENTAL
Intervention: rVSV-ZEBOV vaccine (3 million PFU or more)
Number of subjects: 158
Study 25830326 — intervention group
Group type: EXPERIMENTAL
Intervention: rVSV-ZEBOV vaccine
Number of subjects: 158
Study 24246588 — intervention group
Group type: EXPERIMENTAL
Intervention: Family heart‐health intervention (n = 211)
Number of subjects: 426
Study 24246588 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 215)
Number of subjects: 426
Study 22055281 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic self-help CBT (n = 216)
Number of subjects: 623
Study 22055281 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper-and-pencil self-help CBT (n = 205)
Number of subjects: 623
Study 22055281 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control (n = 202)
Number of subjects: 623
Study 22055281 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic and paper-and-pencil groups (n = 421 combined)
Number of subjects: 623
Study 20542468 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-receptor blockers (ARBs)
Number of subjects: 93515
Study 20542468 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 93515
Study 18760207 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified mattress locking stitch (MMLS) repair
Number of subjects: 78
Study 18760207 — intervention group
Group type: COMPARATOR
Intervention: Simple stitch repair
Number of subjects: 78
Study 16190390 — intervention group
Group type: EXPERIMENTAL
Intervention: General therapy and UTI after hemorrhage (Group II)
Number of subjects: 66
Study 16190390 — intervention group
Group type: EXPERIMENTAL
Intervention: General therapy (Group I)
Number of subjects: 66
Study 16190390 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 patients without hemorrhage)
Number of subjects: 66